Year-over-year earnings per share growth for the last twelve months: ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX) possesses colossal pricing power due to unique NK-cell activation amid inelastic demand. The quarterly EPS gap clearly demonstrates profit dynamics, where the -110.40 level indicates the parameter's status. High R&D expenditures and patent protection create stringent barriers to entry. FDA approval has opened access to patients, ensuring maximum loyalty and expansion for the company.
Comprehensive metric breakdowns and analytics for NantKwest (IBRX)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- book capitalization data:
- debt and liquidity details:
- earnings and market multiples details:
IBRX - Final Profit|Projected Future Earnings ImmunityBio, Inc.|IBRX - Market Cap to Earnings|Future Price to Earnings ImmunityBio Corp|IBRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple ImmunityBio Corp|IBRX - Operating profit EBITDA|Earnings per share for the last twelve months ImmunityBio|IBRX - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months immunitybio.com|IBRX - Earnings per share growth rate in current year|Earnings growth forecast for next year ImmunityBio, Inc.
Comprehensive company analysis:ImmunityBio, IBRX
Stress testing assets requires an analysis of net income dynamics to confirm strategic resilience. ImmunityBio, Inc. (IBRX) faces colossal clinical trial costs and regulatory barriers within immunotherapy. Quarterly earnings per share growth measures the percentage change in EPS, reflecting the efficiency of development capitalization. This chart allows for an assessment of the pace of transition from the investment stage to profit generation. Positive dynamics would confirm the commercial maturity of the business.
Competitors of ImmunityBio, Inc.
IMCR: Quarterly EPS earnings growth|JANX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcus Bio|Year-over-year net earnings per share growth for the last 12 months Zymeworks Biopharmaceuticals (ZYME)|Year-over-year earnings per share growth for the last twelve months Tango Therapeutics (TNGX)|Year-over-year net earnings per share growth for the last 12 months iovance.com IOVA|Immatics - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Xencor Inc XNCR|CMPX - Year-over-year earnings per share growth for the last twelve months|REPL (Replimune Inc.) - Year-over-year earnings per share growth for the last 12 months|Lyell Immunopharma (LYEL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months innate-pharma.com (IPHA)|Year-over-year net earnings per share growth for the last 12 months PYXS|CGEN - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months IOBT (IO Biotech Corp)|Year-over-year earnings per share growth rate for the last twelve months STRO|Quarterly EPS earnings growth INKT (MiNK Therapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months HOWL|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months alxoncology.com|Cue Biopharma (CUE) - Year-over-year earnings per share growth for the last twelve months|PDS Biotechnology Corporation - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIABiotech.com|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Corp - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics Inc (LPTX) - Earnings per share growth in annualized terms for the last twelve months|Intensity Tx - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Sensei Biotherapeutics SNSE|Theriva Biologics (TOVX) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Gritstone bio|Year-over-year earnings per share growth for the last twelve months Kineta Bio|Year-over-year net earnings per share growth for the last 12 months NexImmune Corporation (NEXI)|Year-over-year net earnings per share growth for the last 12 months TSBX (Turnstone Biologics)|Quarterly EPS earnings growth vaccinex.com (VCNX)|Year-over-year earnings per share growth for the last twelve months Harpoon Therapeutics, Inc. HARP
